IDEXX Laboratories
Provides veterinary diagnostics, reference laboratories, and practice software for connected clinical workflows.
Something off on this page? Send us feedback.
Profile
Sells in-clinic analyzers and consumables, rapid assays, reference-laboratory testing, veterinary software and imaging, plus smaller water and livestock diagnostics businesses. The Companion Animal Group produces most revenue, with instrument placements supporting recurring consumable demand.
Develops veterinary point-of-care instruments, consumables, rapid assays and imaging systems, while operating reference laboratories, telemedicine services and practice-management software. Companion Animal Group integrates these tools for companion-animal clinics; smaller activities serve biomedical research and human point-of-care diagnostics.
Most revenue comes from Companion Animal Group. Placements of proprietary in-clinic analyzers expand an installed base that supports recurring consumable demand, while laboratory testing, telemedicine and software extend the customer workflow. Water products detect microbiological contaminants; Livestock, Poultry and Dairy supplies herd-health and milk-safety tests.
Serves customers across major global regions, with the United States the largest market. Breadth across clinic testing, reference labs and information management supports an integrated diagnostic workflow. Results depend on companion-animal diagnostic demand, instrument placements and use, regulatory acceptance for certain tests, and continuity from sole- and single-source suppliers.
Company facts
Key statistics
Year to date −17.2% · Average volume (30d) 547.6K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 11, 2026 | Barclays | Reiterate | Overweight | $800 | $710 |
| Jul 27, 2026 | UBS | Reiterate | Neutral | $640 | $620 |
| Apr 28, 2026 | UBS | Reiterate | Neutral | $730 | $640 |
| Feb 9, 2026 | Piper Sandler | Reiterate | Neutral | $750 | |
| Feb 5, 2026 | Barclays | Reiterate | Overweight | $850 | $800 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $3.94 | $4.27 | +8.4% | $1.20B | $1.22B | +1.4% | +3.57% |
| May 5, 2026Q1 FY26 | $3.41 | $3.47 | +1.8% | $1.12B | $1.14B | +2.0% | +2.89% |
| Feb 2, 2026Q4 FY25 | $2.93 | $3.08 | +5.1% | $1.07B | $1.09B | +1.7% | −1.10% |
| Nov 3, 2025Q3 FY25 | $3.14 | $3.40 | +8.3% | $1.07B | $1.11B | +3.0% | −0.11% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $998.4M | $1.11B | $1.11B | $1.09B | $1.14B | $1.22B | |
| Gross profit | $623.4M | $694.7M | $683.4M | $658.1M | $722.7M | $779.1M | |
| Operating income | $316.5M | $373.0M | $354.8M | $315.6M | $362.6M | $425.6M | |
| Net income | $242.7M | $294.0M | $274.6M | $248.2M | $278.4M | $338.4M | |
| Diluted EPS | $2.96 | $3.63 | $3.40 | $3.08 | $3.45 | $4.19 | |
| Gross margin | 62.4% | 62.6% | 61.8% | 60.3% | 63.4% | 64.0% | |
| Operating margin | 31.7% | 33.6% | 32.1% | 28.9% | 31.8% | 35.0% |
Fiscal years (4-quarter sums)FY21 $3.22B · FY22 $3.37B · FY23 $3.66B · FY24 $3.90B · FY25 $4.30B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $196.9M · Total debt $1.10B · Total assets $3.44B · Shareholders' equity $1.61B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 78.88M · Float 78.58M · 99.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 8.17M | 10.36% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 5.15M | 6.53% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 3.90M | 4.94% | 13F | Aug 13, 2026 |
| State Street Corp | 3.75M | 4.75% | 13F | Aug 7, 2026 |
| Invesco Ltd. | 3.61M | 4.58% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 3, 2026 | Nimrata Hunt | officer: Executive Vice President | −1,758 | $634.57 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | director, officer: President and CEO | −23,326 | $657.55 |
| Feb 26, 2026 | Nimrata Hunt | officer: Executive Vice President | −2,693 | $661.54 |
| Feb 17, 2026 | Sophie V. Vandebroek | director | −1,464 | $628.62 |
| Feb 17, 2026 | Michael G. Erickson | officer: Executive Vice President | −5,371 | $627.38 |
Peers
- Zoetis
Global animal health leader; Vetscan in-clinic analyzers compete head-to-head.
- Thermo Fisher Scientific
Named in IDEXX 10-K for LPD/water; Indiko chemistry for vet clinics.
- Neogen
Named in IDEXX 10-K; livestock diagnostics, genomics, and food safety overlap.
- Danaher
Hach water brand competes with Colilert; Beckman Coulter adjacent in lab.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| IDEXX Laboratories | $554.99 | +0.09% | $43.78B | 39.3 | 35.6 | 9.6 | +9.7% |
| Zoetis | $77.47 | +0.23% | $32.42B | 12.7 | 12.5 | 3.4 | +0.3% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Neogen | $11.66 | 0.00% | $2.54B | — | 39.8 | 2.9 | −0.1% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Median | 33.5 | 24.0 | 4.2 | +2.9% |